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Prostaglandin E2 (PGE2) upregulation in response to UV light exposure is a significant factor in the development
of non-melanoma skin cancer. It is known that PGE2 signals via the E prostanoid receptors, EP1–4, but the role
that each receptor plays in skin carcinogenesis is unclear. Immunohistochemical analysis of EP receptor staining
in unirradiated and UVB-exposed SKH-1 mouse skin demonstrated the localization of EP1 and EP2 to the plasma
membrane of differentiated epidermal keratinocytes. In contrast, the EP3 receptor localized to the basal layer of
the epidermis in unirradiated skin and throughout the epidermis in UVB-exposed skin. In unirradiated skin,
cytoplasmic EP4 staining was seen throughout the epidermis, in dermal leukocytes, and in vascular
endothelium. However, UVB exposure resulted in relocalization of the EP4 receptor to the plasma membrane
of keratinocytes, with no change in the dermal staining pattern. In tumors isolated from UVB-exposed mice, EP1
and EP2 staining was detected in the more differentiated cells surrounding keratin pearls, whereas EP3 and EP4
were detectable throughout the tumors. Differential expression of the EP receptors suggests that each receptor
may play a distinct role in skin tumor development.
Journal of Investigative Dermatology(2007) 127, 214–221. doi:10.1038/sj.jid.5700502; published online 17 August 2006
INTRODUCTION
Prostaglandins, key components of the prostanoid group of
lipid mediators, are expressed in many cell types, both
constitutively and in response to a wide variety of environ-
mental, physiological, and pathological stimuli. The cycloox-
ygenase (COX) enzymes, COX-1 and COX-2, carry out the
initial stages of the conversion of arachidonic acid to
prostaglandins. COX-1 is expressed constitutively in many
tissues, whereas COX-2 is transiently induced in response to
inflammatory stimuli and is expressed at high levels in many
cancers (Wang and Dubois, 2006). A number of studies have
demonstrated persistently elevated expression of COX-2 in
chronically UVB-irradiated skin, as well as in UVB-induced
pre-malignant lesions and squamous cell carcinomas (Buck-
man et al., 1998; Athar et al., 2001; An et al., 2002). A role
for COX-2 in photocarcinogenesis is also supported by
several studies demonstrating that inhibition of COX-2
activity by selective COX-2 inhibitors can diminish UVB-
mediated tumor growth (Fischer et al., 1999; Pentland et al.,
1999; Orengo et al., 2002; Wilgus et al., 2003). Prostaglandin
E2 (PGE2), the primary product of COX-2 in the skin, exerts its
effects by binding to one of four E prostanoid (EP) receptors,
designated EP1, EP2, EP3, and EP4. Although the roles of
COX-2 and PGE2 in UVB-induced skin cancer development
have been well documented, the roles of the receptors that bind
PGE2 during this process have not been well characterized.
The EP receptors have been characterized based on their
response to and affinity for various agonists and antagonists
(Ichikawa et al., 1996). PGE2, the most potent ligand for the
EP receptors, binds with varying affinities to each of the four
receptors (Kiriyama et al., 1997). The EP receptors are
G-protein-coupled rhodopsin-type receptors with distinct
signal-transduction properties. EP1 is coupled to an uni-
dentified G protein and two distinct signaling pathways that
result in an increase in intracellular calcium (Watabe et al.,
1993; Katoh et al., 1995). The EP2 and EP4 receptors are both
coupled to the stimulatory G protein (Gs) and, when
activated, induce adenylate cyclase activity, resulting in an
increase in cAMP (Honda et al., 1993; Regan et al., 1994).
Activation of the EP2 receptor, however, results in a cAMP
response that is much greater than that of the EP4 receptor
(Fujino et al., 2002). The EP3 receptor is the only mouse EP
receptor known to be alternatively spliced, yielding three
variants, EP3a, EP3b, and EP3g. The ligand binding properties
of the EP3 splice variants are identical, but the G-protein
coupling and therefore the signal-transduction properties vary
(Irie et al., 1993; Sugimoto et al., 1993). EP3a and EP3b have
been shown to inhibit the activation of adenylate cyclase via
coupling to the inhibitory G protein (Gi) (Sugimoto et al.,
1993), whereas EP3g has been shown to have both
stimulatory and inhibitory effects on adenylate cyclase by
binding to both Gi and Gs (Irie et al., 1994a). In addition to
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affecting adenylate cyclase activity, the EP3 isoforms also
induce increases in intracellular calcium concentrations. This
was shown to be due to Gi-mediated phospholipase C
activation (Irie et al., 1994b), a different mechanism from the
one by which EP1 mediates increases in intracellular calcium
concentration. Although the role for the EP receptors in
epithelial malignancies such as breast and colon cancer has
been clearly documented (Watanabe et al., 1999, 2000;
Kawamori et al., 2001, 2005), the role for these receptors in
skin carcinogenesis remains to be completely elucidated.
Recent studies have demonstrated the differential distribu-
tion of EP1, EP2, and EP3 in the adult human epidermis
(Konger et al., 2005a, b). Potential signaling pathways
involving calcium induction by EP1; cAMP induction, growth
stimulation, and invasiveness by EP2; and diacylglycerol
release, ceramide release, and growth inhibition by EP3 have
also been demonstrated in human keratinocytes (Konger
et al., 1998, 2002, 2005a, b). In mice, EP3 was shown to
promote arachidonic acid-induced inflammation in the
murine ear (Goulet et al., 2004), but to attenuate allergic
inflammation in mice (Kunikata et al., 2005), indicating that
EP3 may play a very complex role in inflammation, a process
known to be integral to skin carcinogenesis. An earlier study,
using a cell line, demonstrated that growth of skin tumor cells
depends on PGE2 signaling via the EP1 receptor (Thompson
et al., 2001). We recently demonstrated a significant decrease
in acute UVB-mediated inflammation and a 50% reduction in
tumor development with topical application of the EP1
receptor antagonist ONO-8713, demonstrating a role for this
receptor in skin carcinogenesis (Tober et al., 2006). Taken
together, these studies indicate that the EP receptors may
have differential roles in skin tumor development.
It is clear that the arachidonic acid pathway is important in
carcinogenesis based upon the numerous studies document-
ing the chemopreventive nature of non-steroidal anti-
inflammatory drugs and selective COX-2 inhibitors (Wang
and Dubois, 2006). However, given the cytotoxic and
cardiotoxic effects recently linked to non-steroidal anti-
inflammatory drugs and selective COX-2 inhibitor use
(Spektor and Fuster, 2005), targeting the EP receptors may
provide an alternative mechanism for blocking the carcino-
genic properties of COX-2 while potentially limiting the toxic
side effects of direct COX blockade. In order to determine if
targeting the EP receptors is a viable option for inhibition of
skin cancer development, the roles of each receptor in the
skin need to be more clearly defined. A recent paper by Lee
et al. (2005) demonstrated differential EP receptor localiza-
tion patterns in skin and tumors of mice exposed to UVB and
in chronically UVB-exposed human skin containing pre-
malignant and malignant lesions. The goal of the present study
was to examine the mRNA levels of each of the EP receptors
and their splice variants and to localize EP1–4 proteins in the
skin of SKH-1 mice following acute UVB irradiation and in the
skin and tumors of mice exposed to chronic UVB irradiation.
Based on our previously published study (Tober et al., 2006)
and the results of the present study, the EP3 as well as the EP1
receptor may contribute to UVB-mediated inflammation and,
ultimately, to tumor development.
RESULTS
Immunohistochemical localization of the EP receptors in SKH-1
hairless mouse skin
To assess the effects of UVB on EP receptor expression,
immunohistochemistry for the individual receptors was
performed on skin and tumors ranging in grade from
papilloma to micro-invasive squamous cell carcinoma
harvested from SKH-1 hairless mice. Expression of both the
EP1 (Figure 1a) and EP2 (Figure 1b) receptors was low but
detectable in unirradiated control skin. Immunoreactivity was
primarily localized to the more differentiated keratinocytes in
the outermost layers of the skin, including the stratum
corneum and stratum granulosum. EP1 protein (Figure 1a,
c, e, and g) was localized specifically to the plasma
membrane, whereas the EP2 receptor (Figure 1b, d, f, and
h) was found both on the plasma membrane and within the
cytoplasm. In response to either acute or chronic UVB
exposure, there was no change in the localization of either
the EP1 (Figure 1c and e) or EP2 (Figure 1d and f) receptor. In
both papillomas and microinvasive squamous cell carcino-
mas (as graded by Dr Donna Kusewitt, a board-certified
veterinary pathologist) arising in response to chronic UVB
exposure, EP1 (Figure 1g) and EP2 (Figure 1h) proteins were
found only in the highly differentiated cells surrounding
keratin pearls. Unlike the EP1 or EP2 receptor, the EP3
receptor localized to the proliferative basal compartment of
the epidermis in unirradiated mouse skin and to dermal
sebocytes (Figure 2a). Expression of the EP3 receptor was
cytoplasmic and perinuclear in the epidermis and localized
to the plasma membrane in dermal sebocytes. At 48 hours
following a single exposure to UVB, EP3 receptor expression
was seen throughout all layers of the epidermis (Figure 2b
and c). This distinctive epidermal relocalization was not seen
at 24 hours following a single UVB exposure or after four
UVB exposures given over the course of a week (data not
shown). Interestingly, the expression pattern of the EP3
receptor in chronically irradiated skin was very similar to
that seen at 48 hours following a single UVB exposure (Figure
1d). In tumors of all grades arising in chronically irradiated
mice, EP3 receptor expression was heterogeneous both in
distribution and intensity (Figure 2e). EP4 receptor immuno-
reactivity was present in the majority of epidermal keratino-
cytes (Figure 3a) and dermal leukocytes and in some dermal
endothelium in unirradiated mouse skin. Exposure to either
acute (Figure 3b and c) or chronic (Figure 3f) UVB induced
EP4 relocalization to the plasma membrane in the more
highly differentiated cells of the stratum granulosum,
although the diffuse cytoplasmic staining pattern was
maintained throughout the rest of the epidermis. Immuno-
positive infiltrating inflammatory cells (Figure 3d) and
endothelium (Figure 3e) were also clearly visible in the
dermis of acutely and chronically irradiated mice. The
primary localization of the EP4 receptor in tumors, regardless
of grade, arising in UVB-treated mice was in the plasma
membrane of the highly differentiated cells surrounding the
keratin pearls. However, a diffuse cytoplasmic staining
pattern was maintained throughout much of the rest of the
tumors (Figure 3g). In addition, EP4 expression in the
www.jidonline.org 215
KL Tober et al.
E Prostanoid Receptor Expression in Murine Skin
inflammatory leukocytes and endothelium was visible in the
uninvolved normal dermis adjacent to tumors, but was less
prominent in leukocytes and vascular endothelium located
within the tumor itself (data not shown). Specificity of the EP
receptor antibodies was demonstrated by complete loss of
staining when the primary antibodies were pre-absorbed with
non-immune EP1 (Figure 1i), EP2 (Figure 1j), EP3 (Figure 2f),
or EP4 (Figure 3h) blocking peptide or when the primary or
secondary antibody was replaced with blocking solution
(data not shown). Pre-absorption of the primary antibodies
with irrelevant blocking peptides had no effect on staining
(data not shown).
EP receptor mRNA expression in SKH-1 hairless mouse skin
In order to assess levels of EP receptors expression in the skin,
we performed semiquantitative reverse transcription-PCR on
total RNA isolated from the dorsal skin of unirradiated (N),
acutely irradiated (A), or chronically irradiated (C) mice, and
on total RNA isolated from tumors (T) arising in chronically
irradiated mice. Net intensity of the EP receptor bands was
compared to the net intensity values of bands obtained by
amplification of the housekeeping gene hypoxanthine-gua-
nine phosphoribosyltransferase (HPRT). All of the EP recep-
tors were expressed in unirradiated skin. Acute exposure to
UVB induced statistically significant decreases in all but EP1
and EP3g (Figure 4a and b). No significant changes in
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Figure 1. Immunofluorescent localization of EP1 and EP2 receptors in
skin and tumors isolated from hairless mice. (a, b) EP1 and EP2 receptor
expression is demonstrated in unirradiated skin. (c, d) Skin of mice 48 hours
after exposure to UVB light. (e, f) Skin of mice following 25 weeks of three
times weekly UVB exposure and in (g, h) tumors arising in chronically
irradiated mice. Specificity of (i) EP1 and (j) EP2 antibodies is demonstrated
by lack of staining upon pre-incubation of primary antibody with the
specific blocking peptide. All photomicrographs were taken at an original
magnification of  60, (bar¼ 50 mm; KP¼ keratin pearl).
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Figure 2. Immunofluorescent localization of EP3 receptor in skin and tumors
isolated from hairless mice. (a) Expression of the EP3 receptor is demonstrated
in skin of untreated mice, (b, c) mice exposed to a single dose of UVB and
killed at 48 hours after exposure, (d) mice exposed to UVB three times weekly
for 25 weeks, and in (e) tumors of mice that were exposed to UVB three times
weekly for 25 weeks. (f) Specificity of the EP3 receptor was demonstrated by
a lack of staining upon pre-incubation of the EP3 antibody with the EP3-
blocking peptide. Photographs depicted in (a, b, d, e, and f) were taken at an
original magnification of  60 (bar¼ 50mm) whereas the photograph in
(c) was taken at an original magnification of  100 (bar¼ 20 mm).
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expression of EP1, EP4, EP3a, and EP3g were detectable in
chronically irradiated skin compared to unirradiated skin.
However, EP2 levels were significantly elevated and EP3b
levels were significantly reduced in skin isolated from
chronically irradiated mice (Figure 4a and b). In tumors
isolated from chronically irradiated mice, EP1 expression was
significantly higher and EP3a and EP3b expression was
significantly lower than in unirradiated skin. Expression of
EP2, EP4, and EP3g did not appear to be altered in tumors
isolated from chronically irradiated mice compared to
unirradiated skin (Figure 4a and b).
DISCUSSION
The involvement of PGE2 in skin carcinogenesis is well
established, with much of the evidence based on studies
utilizing specific COX-2 inhibitors. Although COX-2 inhibi-
tors can reduce both inflammation and the emergence of skin
tumors in response to UVB, they do not completely block
either PGE2 production or tumor development (Fischer et al.,
1999; Pentland et al., 1999; Wilgus et al., 2000, 2003;
Orengo et al., 2002). Even in the presence of COX-2
inhibitors, it appears that residual PGE2 binds to EP receptors
to stimulate signal-transduction pathways involved in skin
tumor development. It was recently demonstrated that EP1
receptor expression is primarily localized to the highly
differentiated cells within the epidermis in both murine and
human skin (Konger et al., 2005a; Tober et al., 2006) and that
activation of EP1 induces increases in intracellular calcium
(Konger et al., 2005a). These findings suggest that EP1 may
mediate keratinocyte differentiation. It has also been demon-
strated that growth of cultured skin tumor cells depends on
PGE2 signaling via the EP1 but not the EP4 receptor
(Thompson et al., 2001). We demonstrated that ONO-
8713, a specific antagonist of the EP1 receptor, was able to
significantly reduce UVB-induced inflammation and also to
inhibit tumor formation by 50% (Tober et al., 2006). Taken
together, these studies indicate a role for the EP1 receptor in
murine squamous cell carcinogenesis. EP receptors are thus
likely to play an important role in skin carcinogenesis, and a
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Figure 3. Immunohistochemical localization of EP4 receptor in skin and
tumors isolated from hairless mice. (a) Specific expression of the EP4 receptor
is demonstrated in the skin of unirradiated mice, (b, c, d, and e) skin of mice
48 hours after a single exposure to UVB light, (f) mice chronically exposed to
UVB, and in (g) tumors isolated from mice chronically exposed to UVB.
(h) The specificity of the EP4 antibody is demonstrated by the lack of staining
after pre-incubation of the primary antibody with EP4-blocking peptide.
Photomicrographs in (a, b, f, g, and h) were taken at an original magnification
60 (bar¼ 50mm) and those taken in (c, d, and e) were taken at an original
magnification  100 (bar¼ 20 mm). N¼nuclear; PM¼plasma membrane;
E¼ endothelium; Leuk¼ leukocyte; KP¼ keratin pearl).
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Figure 4. EP receptor mRNA expression in skin and tumors isolated from
hairless mice. (a) Reverse transcription-PCR analysis was performed on total
RNA extracted from skin of unirradiated mice (N), acutely irradiated mice (A),
chronically irradiated mice (C), and tumors arising in chronically irradiated
mice (T). Graphical representation of gene expression analysis of EP1, EP2,
and EP4 (b) EP3a, EP3b, and EP3g demonstrates the variability in expression in
each of these mRNA transcripts. Statistical analysis using Student’s t-test
demonstrated statistically significant (*Pp0.05) differences in UVB-exposed
skin and tumors compared to unirradiated skin.
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better understanding of these receptors may improve our
chemopreventive and chemotherapeutic strategies.
Because of the number and diverse actions of the PGE2
receptors in the skin, the role of these receptors in skin
carcinogenesis is complex. In an attempt to begin to dissect
the part that the individual EP receptors play in this process,
we determined the location and level of expression of these
receptors in the skin. Using immunofluorescent and immuno-
histochemical techniques, we demonstrated, using antibodies
from Alpha Diagnostics Inc., (San Antonio, TX) that the EP1,
EP2, EP3, and EP4 receptors were expressed in different cell
types and at different subcellular locations in untreated
murine skin. Currently, there are two commercially available
sources of murine EP receptor antibodies, Cayman Chemical
and Alpha Diagnostics Inc. Our studies were initiated using
an antibody directed against EP1 manufactured by Cayman
Chemical. Immunohistochemical analysis of EP1 receptor
staining using this antibody demonstrated plasma membrane-
specific staining of the EP1 receptor only in highly
differentiated keratinocytes of the epidermis (Figure S1a).
However, a change in the lot of this EP1 antibody yielded
nonspecific staining throughout the entire epidermis (Figure
S1b and c). A third lot of the Cayman antibody gave similar
nonspecific epidermal EP1 localization (not shown). As an
alternative source, we tested several lots of EP receptor
antibodies from Alpha Diagnostics Inc. The EP1 antibody
staining pattern was identical to that of the original Cayman
Chemical EP1 antibody lot (Tober et al., 2006; Figure S1d),
and Figure 1a, c, e, g, and i. Additionally, multiple lots of the
EP1 antibody from Alpha Diagnostics Inc. yielded identical
staining patterns with both immunofluorescent and immuno-
histochemical techniques. Based on these initial studies, we
used Alpha Diagnostics Inc. EP1, EP2, EP3, and EP4
antibodies in the current study. Our data on the localization
of each of the EP receptors differ from those recently reported
by Lee et al. (2005) in which Cayman Chemical EP receptor
antibodies were used. Several possibilities might explain the
discrepancy between the two results. One possibility is that
the experimental design varied between the two studies.
However, upon examination, the age of mice at the onset of
UVB exposure, the amount of UVB, and the time that the
mice were exposed were nearly identical between the two
studies. Additionally, immunohistochemical procedures of
Lee et al. (2005) were different from our procedures. We
tested this as a possibility by using Lee’s published protocol
and our protocol with the Cayman Chemical antibodies. We
found that switching the protocols did not affect the observed
staining patterns of the antibodies. It is possible that
differences in formalin fixation time, our tissues were fixed
in formalin for only 2 hours where Lee’s tissues were fixed
overnight, is a contributing factor to the observed different
staining patterns. Although use of a third primary antibody
source would be ideal to confirm either staining pattern,
currently those antibodies are not commercially available.
In the current study, EP1 and EP2 expression was localized
to the highly differentiated compartment of the epidermis,
whereas EP3 localized specifically to the proliferative basal
cells. Recently, Konger et al. (2005a, b) demonstrated a
similar pattern of EP1, EP2, and EP3 immunolocalization in
adult human epidermis to that seen in the current study in
murine skin. The present study demonstrated diffuse cyto-
plasmic expression of the EP4 receptor throughout the
epidermis in untreated murine skin. We also showed that
dermal leukocytes and some dermal endothelium expressed
this receptor. Our demonstration of vascular localization of
EP4 is supported by recent studies indicating that COX-2 may
colocalize with EP4 in arteries of the human kidney (Therland
et al., 2004) and that EP4 may play a direct role in vascular
relaxation in pigs (Wilson and Giles, 2005).
In response to either acute or chronic UVB exposure,
stratum granulosum localization of the EP1 and EP2 receptors
remained unchanged. It is known that EP1 signaling results in
an increase in intracellular calcium (Watabe et al., 1993;
Katoh et al., 1995), a potent factor in inducing keratinocyte
differentiation. It has also been shown that signaling via EP2
can induce keratinocyte proliferation (Konger et al., 1998).
Taken together, these studies and our current findings
indicate that EP1 and EP2 may serve to balance the opposing
processes of proliferation and differentiation in epidermal
keratinocytes. In our tumors, regardless of grade, arising in
chronically irradiated mice, EP1 and EP2 localized primarily
to the cells surrounding keratin pearls, highly differentiated
structures within the tumors.
The EP3 receptor was dramatically altered in response to
both acute and chronic UVB exposure. Under normal
conditions, EP3 was expressed only in epidermal basal cells.
However, its expression was detectable throughout the entire
epidermis at the peak of UVB-induced inflammation,
48 hours following a single UVB exposure, and after
25 weeks of three times weekly UVB exposure. This
relocalization did not occur at either 24 hours or 1 week
following UVB (not shown), indicating that this receptor may
be tightly associated with both peak acute and chronic UVB-
induced inflammation. Previous studies examining this
receptor found that the ears of EP3 knockout mice demon-
strated a decreased edema response to exogenously applied
arachidonic acid (Goulet et al., 2004). However, allergic
inflammation, as measured by leukocyte infiltration, was
actually enhanced in EP3 knockout mice (Kunikata et al.,
2005). Recent studies utilizing the chemically driven model
of multistage skin carcinogenesis demonstrated that EP3
knockout mice had delayed tumor onset, but showed no
difference in tumor multiplicity (Shoji et al., 2005; Sung et al.,
2005). These studies do not describe a role for EP3 in
chemically induced skin tumor formation; however, the role
of this receptor in UVB-induced skin carcinogenesis is not yet
known. Thus, it is possible that EP3 plays a role in UVB-
induced skin carcinogenesis while it does not have a role in
the chemical model.
Our present results indicate that EP3 expression in UVB-
induced tumors, regardless of grade, is heterogeneous both in
location and level. A possible explanation for the hetero-
geneous tumor localization and the inflammation-induced
relocalization of EP3 is that this receptor is the only EP
receptor that is alternatively spliced. Commercially available
EP3 antibodies, including the antibody used in the present
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studies, recognize epitopes near the N terminus of EP3 that
are present in all of the EP splice variants. Using these
antibodies makes it impossible to differentiate among splice
variants. In order to examine changes in EP3 receptor splice
variants, we examined changes in gene expression. Using
reverse transcription-PCR analysis, we showed that EP3a and
EP3g were significantly decreased at 48 hours following UVB
exposure and in tumors arising in chronically irradiated mice
compared to unirradiated skin. We also showed that EP3g
was decreased in acutely irradiated skin compared to
unirradiated skin. The decrease in EP3 mRNA at 48 hours
following UVB is inconsistent with the increased EP3 protein
that we showed at this time point. However, this mRNA
decrease may account for the lack of UVB-induced EP3
protein relocalization seen after 1 week of UVB exposure (not
shown). Our RT-PCR results are similar to those seen in Lee
et al. (2005) suggesting that EP3 receptor gene expression
may be downregulated by UVB. However, both our results
and those of Lee et al. (2005) demonstrate gene expression in
whole skin. It may be necessary to examine expression of the
EP receptors in epidermal tissue as opposed to whole skin as
EP3 alterations that occur at the protein level are specific to
the epidermis and alterations at the mRNA level may be lost
when examining whole skin. Our data suggest that further
investigation into the role of the various splice variants of the
EP3 receptor in mediating normal homeostasis and UVB-
induced carcinogenesis in the skin seems to be warranted.
Little is known about the importance of the EP4 receptor in
UVB-induced inflammation and tumorigenesis. In this study,
the primary alteration in EP4 expression in response to either
acute or chronic UVB exposure was the relocalization of the
receptor from the cytoplasm to the plasma membrane of
keratinocytes in the more differentiated layers of the
epidermis. It has been demonstrated that EP4 plays a role in
Langerhans cell migration and maturation (Kabashima et al.,
2003). Perhaps, our current demonstration of the cellular
redistribution of EP4 in response to UVB exposure indicates
activation of this receptor, which may be required to initiate a
skin immune response. Dermal localization of EP4 in the skin
of mice exposed to UVB, while more pronounced due to
heightened inflammatory cell infiltration and vascular dila-
tion, remains unchanged. Further studies defining the role of
this receptor in the epidermis and dermis are clearly needed.
This study demonstrated that the EP receptors were
expressed in varying compartments and at varying levels in
normal skin and were differentially regulated in response to
UVB light. In support of this, recent reports have demon-
strated similar findings in human (Konger et al., 2005a, b)
skin. Although it is known that inhibition of PGE2 production
inhibits tumor development, it is also known that COX-2
inhibitors can have deleterious cardiac side effects making
other mediators of arachidonic acid metabolism more
attractive targets for chemopreventive or chemotherapeutic
strategies for skin cancer. Our recent demonstration of the
effectiveness of EP1 antagonism in reducing UVB-mediated
tumor development (Tober et al., 2006), taken together with
the current study demonstrating the differential expression of
EP receptors in the skin, suggests that the EP receptors may be
effective targets for the prevention and or treatment of UVB-
mediated skin tumor development.
MATERIALS AND METHODS
Animal treatment
Female SKH-1 hairless mice (Charles River Laboratories, Wilming-
ton, MA) were housed in the vivarium at The Ohio State University
according to the requirements established by the American
Association for Accreditation of Laboratory Animal Care. Before
beginning all studies, procedures were approved by the appropriate
Institutional Animal Care Utilization Committee. Mice that were
irradiated were exposed dorsally to one minimal erythemic dose of
UVB (2240 J/m2 as determined by a UVR meter; UVP Inc., Upland,
CA) emitted by Phillips FS40UVB lamps (American Ultraviolet
Company, Lebanon, IN) that were fitted with TA422 Kodacel filters
(Eastman Kodak, Rochester, NY) to ensure the exclusion of UVC light
and emission primarily of UVB light (290–320 nm).
Four groups of SKH-1 hairless mice were used for examination of
the effects of acute UVB-mediated inflammation on the expression of
EP receptors. Groups 1 and 2, n¼ 8, were exposed to a single dose of
UVB followed immediately by topical application of 400 ml acetone
and killed at 24 hours (group 1) or 48 hours (group 2) following
treatment. Group 3, n¼ 8, was dorsally irradiated and topically
treated every other day for a week (four exposures) and killed at
48 hours following the final combination of exposure and topical
treatment. Group 4, n¼ 10, was exposed dorsally to UVB followed
by application of 400 ml acetone three times weekly on non-
consecutive days for 25 weeks and killed 24 hours following the final
UVB exposure. This treatment schedule is in accordance with our
previously published protocol for this strain of mice (Wilgus et al.,
2003). At the time of killing, skin, tumors, and non-tumor bearing
skin were fixed in 10% neutral-buffered formalin (Thermo-Shandon,
Waltham, MA) for immunohistochemical evaluation of EP receptor
expression. Dorsal skin was also harvested from age-matched
unirradiated control mice.
Immunohistochemical detection of the EP receptors
Immediately following killing, skin sections (0.5 cm2) or tumors were
placed in 10% neutral-buffered formalin for 2 hours, washed with
phosphate-buffered saline (Invitrogen, Carlsbad, CA), and then
processed and embedded in paraffin. Tissue sections (5 mm) were
mounted onto Superfrost Plus microscope slides (Fisher Scientific,
Pittsburgh, PA). The tissue sections were deparaffinized by submer-
ging the slides into three separate Clear-Rite 3 (Richard-Allan
Scientific, Kalamazoo, MI) containers for 5 minutes each and
rehydrated in a graded series of alcohols (100%, 2 minutes 2;
75% 4 minutes; 50% 4 minutes) followed by a 5-minute soak in
distilled water. Tissue was circled with a hydrophobic Immedge Pen
(Vector Laboratories, Burlingame, CA) and subjected to antigen
retrieval as follows: antigen unmasking fluid (Vector Laboratories)
was heated for at least 15 minutes in a vegetable steamer, at which
time the tissues were placed in the pre-warmed unmasking fluid for
7 minutes. Slides were kept in the unmasking fluid, but removed
from the steamer and allowed to cool at room temperature for
10 minutes. The sections were rinsed and then submerged in 1
automation buffer (Biomeda Corp., Foster City, CA) for 5 minutes
followed by a 30-minute incubation in 1 casein blocking solution
(Vector casein, diluted in molecular biology grade water from
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Eppendorf, Hamburg, Germany). The tissue was incubated with
anti-EP1 antibody (28 mg/ml; Alpha Diagnostics International, San
Antonio, TX), anti-EP2 antibody (15 mg/ml; Alpha Diagnostics
International), anti-EP3 antibody (15 mg/ml; Alpha Diagnostics
International), or anti-EP4 antibody (30 mg/ml; Alpha Diagnostics
International) diluted in 1 casein solution overnight at 41C in a
humidified chamber. Controls included replacing the primary
antibody with 1 casein, performing a 1 hour pre-incubation of
the tissue with equal amounts of primary antibody and either EP1,
EP2, EP3, or EP4 blocking peptide (Alpha Diagnostics), and replacing
the primary EP receptor antibody with rabbit IgG (30 mg/ml; Vector).
Following the overnight incubation with EP1, EP2, or EP3 primary
antibody or the appropriate negative controls, tissue was rinsed in
phosphate-buffered saline for 5 minutes and incubated with Alexa-
Fluor 488-conjugated goat anti-rabbit secondary antibody (5 mg/ml;
Invitrogen) for 30 minutes at room temperature in a humidified
chamber. For some slides, casein (1 ) was substituted for the
secondary antibody to serve as an additional negative control. Slides
were rinsed with phosphate-buffered saline, then incubated in 40,6-
diamidine-20-phenylindole dihydrochloride solution (0.25 mg/ml;
Invitrogen) for 1 minute at room temperature. Slides were rinsed
with phosphate-buffered saline for 5 minutes, then with distilled
water for 5 minutes as a final wash. Coverslips were mounted with
Prolong Gold mounting media (Invitrogen). Once the mounting
medium was dry, the coverslips were sealed with clear nail polish.
Following overnight incubation of the tissue with EP4 primary
antibody or the associated negative controls, slides were rinsed with
1 automation buffer (Biomeda) and incubated for 30 minutes at
room temp with Rabbit Link (Biogenex, San Ramon, CA). For some
slides, casein (1 ) was substituted for the secondary antibody to
serve as an additional negative control. Tissue was rinsed in
automation buffer for 5 minutes followed by incubation with Rabbit
Label (Biogenex) for 30 minutes at room temp. Tissue was rinsed in
automation buffer for 5 minutes and then incubated with diamino-
benzidine solution (Vector) for 10 minutes, with a final 5-minute
rinse in distilled water. Slides were counterstained with hematoxylin
2 (Richard-Allan Scientific) for 10 seconds, dehydrated through a
graded series of alcohols (75% for 2 minutes, 95% for 2 minutes,
100% for 2 minutes 2) and Clear Rite 3 (5 minutes 2), cover-
slipped, and mounted with Vectamount mounting media (Vector).
Photographs of slides were taken using a Nikon Eclipse E400
microscope with a DXM1200 digital camera equipped with an Y-FL
EPI fluorescence attachment (Tokyo, Japan).
Analysis of EP receptor mRNA expression
Immediately following killing, dorsal skin was harvested and snap
frozen in liquid nitrogen. Total RNA was isolated using Trizol
(Invitrogen) according to the manufacturer’s instructions and purified
using the Micro-to-Midi Total RNA purification system (Invitrogen)
according to the manufacturers instructions. Total RNA (2 mg/10ml)
was heated for 5 minutes at 601C, after which 30 ml of a mixture
containing a final concentration of 1 PCR Buffer II (Life Techno-
logies), 5 mM MgCl2, 1 mM deoxynucleotide-triphosphates (Promega,
Madison, WI), 2.5 mM Oligo-dTs (Midland Certified Reagent Co.,
Midland, TX), 1 U RNAsin (Life Technologies); and 100 U of
Maloney Murine Leukemia Virus-RT (MMLV-RT, Invitrogen) were
added. This mixture was incubated for 60 minutes at 371C followed
by a 5-minute incubation at 951C. The resulting cDNA was used for
all subsequent PCR reactions. Amplification of the HPRT or the EP
receptors cDNA was carried out with 2.5 ml cDNA in a total volume
of 25 ml containing a final concentration of 1 PCR Buffer II
(Invitrogen), 2.5 mM MgCl2 (EP3b) or 1.5 mM MgCl2 (HPRT, EP1,
EP2, EP3a, EP3g, and EP4, Invitrogen), 10% DMSO (EP4 only; Sigma,
St Louis, MO), 1 mM deoxynucleotide-triphosphates (Promega),
200 pmol forward primer, 200 pmol reverse primer, and 0.25 U
Platinum Taq DNA polymerase (Invitrogen). The protocol for
amplification was an initial denaturation for 30 seconds at 951C;
22 cycles of a 15 seconds 951C denaturation step, a 30 seconds 701C
annealing step, and a 30 seconds 721C elongation step (HPRT), 28
cycles of a 15 seconds 951C denaturation step, a 30 seconds 67.11C
annealing step, and a 30 seconds 721C elongation step (EP1); 28
cycles of a 15 seconds 951C denaturation step, a 30 seconds 701C
annealing step, and a 30 seconds 721C elongation step (EP2); 26
cycles of a 15 seconds 951C denaturation step, a 30 seconds 64.31C
annealing step, and a 30 seconds 721C elongation step (EP3a); 26
cycles of a 15 seconds 951C denaturation step, a 30 seconds 67.11C
annealing step, and a 30 seconds 721C elongation step (EP3b); 26
cycles of a 15 seconds 951C denaturation step, a 30 seconds 67.11C
annealing step, and a 30 seconds 721C elongation step (EP3g); and
32 cycles of a 15 seconds 951C denaturation step, a 30 seconds 551C
annealing step, and a 30 seconds 721C elongation step (EP4),
followed by a 7 minutes 721C final elongation step. PCR primers
were synthesized by Invitrogen and the sequences were as follows:
HPRT forward, 50-AGT CCC AGC GTC GTG ATT AGC GAT GAT-30;
HPRT reverse, 50-CCA GCA AGC TTG CAA CCT TAA CCA-30; EP1
forward, 50-TGC TGG TGT TGG TGG TGT TGG CCA TCG-30; EP1
reverse, 50-TGG GCA CAT TCA GAG GTG ACT-30; EP2 forward,
50-GTG GCC CTG GCT CCC GAA AGT C-30; EP2 reverse, 50-GGC
AAG GAG CAT ATG GCG AAG GTG-30; EP3 forward, 50-TGA CCT
TTG CCT GCA ACC TG-30; EP3a reverse, 50-AGC TGG AAG CAT
AGT TGG TG-30; EP3b reverse, 50-GTC CAC TTC AGG TTG TTC
ATC ATC TGG C-30; EP3g reverse, 50-AGA CAA TGA GAT GGC
CTG CC-30; EP4 forward, 50-CGT AGT ATT GTG CAA GTC GC-30;
EP4 reverse, 50-GGC GAT GAG TAA GAT GAC CA-30. All RT-PCR
reactions were carried out in an iCycler thermal cycler (BioRad,
Hercules, CA) and PCR products were visualized on ethidium
bromide stained 1.5% agarose gels, captured, and analyzed using
Kodak DC290 imaging system (Kodak). Net intensity values for
bands arising in complementary DNA samples amplified with EP
receptor gene-specific primers were determined using Kodak 1D
image analysis software (Kodak) and compared in a ratio with net
intensity values for bands from HPRT-amplified complementary
DNAs. These values were graphed to demonstrate the differential
expression of EP receptor mRNA skin and tumors of hairless mice.
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